DONGYING CITY, China, November 3 /PRNewswire/ --

CNPV (NYSE Euronext: ALCNP) (China Solar Photovoltaic SA or the Company), a leading integrated manufacturer of solar photovoltaic products from the production of ingots, wafers and cells to the assembly of SPV modules, founded in 2006, today announced that it filed its first half year Interim Financial Report for the year 2008 ended June 30, 2008 with Alternext of Paris NYSE-Euronext on November 3, 2008. The half year Interim Financial Report can be accessed via the investor relations section of the Company's website at http://www.cnpv-power.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081103/CNM010LOGO )

CALGARY, Canada, November 3 /PRNewswire/ -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that it has achieved positive interim results in its U.K. combination REOLYSIN(R) and docetaxel clinical trial for patients with advanced cancers.

Prof. Hardev Pandha of the Royal Surrey Hospital, U.K., presented the results at the International Society for Biological Therapy of Cancer (iSBTC) annual meeting on November 1, 2008. The meeting was held in San Diego, California from October 31 - November 2, 2008.

Fourteen patients have been treated to date in the dose escalation portion of the trial and eleven patients are evaluable for response. The detailed results are summarized in the following table:

UTRECHT, Netherlands, November 3 /PRNewswire/ --

- Sara Lee to Source 26,500 Tons of Sustainable Coffee in 2009 - Tenfold Increase in Five Years, 30% Increase Compared to This Calendar Year

Sara Lee further increases its commitment to sustainable coffee as the company will buy 26,500 tons of certified coffee beans in 2009. That is approximately 30% more than in 2008 and a tenfold increase since the company formalised its sustainable sourcing commitment five years ago. Sara Lee is the world's third largest coffee roaster and sells its coffee blends under flagship brands such as Douwe Egberts, Senseo, Merrild, Maison du Café and Marcilla.

CALGARY, Canada, November 3 /PRNewswire/ -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that it has achieved positive interim results in its Phase I and Phase II U.K. combination REOLYSIN(R) and paclitaxel/carboplatin clinical trials for patients with advanced cancers. The principal investigator for the trial is Dr. Kevin Harrington of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

The results were presented at the International Society for Biological Therapy of Cancer (iSBTC) annual meeting on November 1, 2008. The meeting was held in San Diego, California from October 31 - November 2, 2008.

MUNICH and GRASBRUNN, Germany, November 3 /PRNewswire/ -- Berlin-based, independent consumer association Stiftung Warentest relies on the payment platform provided by Wirecard AG, one of the leading international providers of electronic payment and risk management solutions. With immediate effect, the Munich-based technology group will handle the entire processing of credit card payments at http://www.test.de.

WAGENINGEN, The Netherlands, November 3 /PRNewswire/ -- The Netherlands and Malaysia have joined forces to dispel the confusion that has arisen surrounding greenhouse gas emissions from oil palm cultivation in tropical peatland areas. Dutch Minister Cramer (Housing, Regional Development and Environment) and Malaysian Minister Chin (Plantation Industries and Commodities) set up the Joint Committee on Carbon Emissions, which is charged to shed light on this subject in the coming years.